Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  DRG Market Assessment Reports

Alzheimer’s Disease – Landscape & Forecast – Disease Landscape & Forecast (G7)

Login to access report north_east
Contact sales account_box

Eisai / Biogen’s lecanemab (Leqembi) and Eli Lilly’s Kisunla (donanemab) have launched for the treatment of early Alzheimer’s disease (AD) in the United States and Japan and, after early headwinds, are nearing market in Europe. Early uptake of the anti-Aβ MAbs has been slow, but market-building efforts to drive awareness and streamline diagnosis are ongoing. New formulations (e.g., subcutaneous lecanemab) and potentially disruptive DMTs (e.g., Roche’s trontinemab, Eli Lilly’s remternetug, Novo Nordisk’s semaglutide) are advancing in the pipeline. Lundbeck / Otsuka’s brexpiprazole (Rexulti) is FDA-approved to treat agitation in AD, and other novel therapies, including Axsome’s dextromethorphan-bupropion (Auvelity) and Karuna’s xanomeline-trospium (Cobenfy), are progressing through late-phase development to treat the neuropsychiatric symptoms of AD. The launch of these potential blockbusters could meaningfully alter this market’s dynamics, driven by unmet clinical need, market demand, and brand-level pricing.

  • How will competition between current and emerging anti-Aβ MAbs evolve through 2034?
  • How do KOLs perceive recently approved and emerging neuropsychiatric therapies for AD? What are the key opportunities for differentiation in this area?
  • What are the key drivers of and constraints on the AD market, and how might they change over the forecast period?
  • What impact could the launch of an oral DMT have on the market?

Product description

Disease Landscape & Forecast offers comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:

  • Optimize your long-term disease and development strategy.
  • Quantify market potential for your pipeline assets and those of your competitors.
  • Understand a disease from top to bottom, including key patient populations, the current and future therapeutic landscape, and the evolving market trajectory.
  • Gauge the commercial outlook and impact of key market events.

Table of contents

Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Gastroesophageal Cancer – Landscape & Forecast – Disease Landscape & Forecast (G7)
Immune checkpoint inhibitors such as Opdivo (Bristol Myers Squibb / Ono Pharmaceutical) and Keytruda (Merck & Co.) have transformed gastroesophageal cancer treatment, driving significant market…
north_east
Report
Multiple Myeloma – Current Treatment – Treatment Sequencing – Multiple Myeloma (US)
Key benefits and usesPinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.Drill down into physicians’ treatment sequences and understand who to position against…
north_east
Report
Multiple Myeloma – Landscape & Forecast – Disease Landscape & Forecast (G7)
The treatment of multiple myeloma is becoming increasingly complex. Sanofi’s Sarclisa received a label expansion for the first-line treatment of autologous stem-cell transplantation-ineligible…
north_east
Report
Epilepsy – Unmet Need – Unmet Need – Dravet Syndrome (US/EU)
Dravet syndrome (DS) is a rare, severe, pediatric-onset genetic epileptic encephalopathy that typically emerges within the first year of life and is marked by developmental delays and multiple…
north_east
Report
Alzheimer’s Disease – Unmet Need – Unmet Need – Agitation in Alzheimer’s Disease (US/EU)
Agitation affects most Alzheimer’s disease (AD) patients and comprises a constellation of disruptive symptoms for patients and their families, which may contribute to nursing home placement…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east